Protagonist Therapeutics ... (PTGX)
38.49
-0.04 (-0.10%)
At close: Feb 20, 2025, 3:59 PM
38.49
0.00%
After-hours: Feb 20, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 37.36 |
| Market Cap | 2.29B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 2.74 |
| PE Ratio (ttm) | 14.05 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 39.55 |
| Volume | 258,174 |
| Avg. Volume (20D) | 620,832 |
| Open | 38.41 |
| Previous Close | 38.53 |
| Day's Range | 37.87 - 39.07 |
| 52-Week Range | 24.22 - 48.89 |
| Beta | undefined |
About PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorder...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2016
Employees 126
Stock Exchange NASDAQ
Ticker Symbol PTGX
Website https://www.protagonist-inc.com
Analyst Forecast
According to 8 analyst ratings, the average rating for PTGX stock is "Buy." The 12-month stock price forecast is $58, which is an increase of 50.69% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Protagonist Therapeutics Inc. is scheduled to release its earnings on Mar 4, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+11.55%
Protagonist Therapeutics shares are trading higher...
Unlock content with
Pro Subscription
5 months ago
+7.45%
Protagonist Therapeutics shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and announced a price target of $60.
